Abstract LB-138: Adjuvant pembrolizumab or placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma: Phase 3 KEYNOTE-630

• Published in: Cancer research (Chicago, Ill.) Vol. 80; no. 16_Supplement; p. LB-138
• Main Authors: Chang, Anne Lynne S., Daniels, Gregory A., Cohen, Ezra E., Ge, Joy Yang, Gumuscu, Burak, Swaby, Ramona F., Geiger, Jessica L.
• Format: Journal Article
• Language: English
• Published: 15.08.2020

Abstract Background: Local recurrence occurs within 5 years in ~20% of patients with high-risk locally advanced cutaneous squamous cell carcinoma treated with current standard-of-care surgical resection and adjuvant radiotherapy. Recent data with programmed death 1 inhibitors have demonstrated antit...